share_log

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Tatsis Ourania

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Tatsis Ourania

福泰制药 | 4：持股变动声明-高管 Tatsis Ourania
美股SEC公告 ·  06/05 16:13
Moomoo AI 已提取核心信息
On June 3, 2024, Ourania Tatsis, EVP, Chief Regulatory & Quality Officer at Vertex Pharmaceuticals Inc. (VRTX), completed a sale of 2,175 shares of common stock at a price of $460 per share. The transaction, conducted on the open market, resulted in a total value of $1,000,500. Following the sale, Tatsis holds a total of 49,098 shares in the company. The sale reflects a direct ownership transaction and is part of the normal course of investment adjustments.
On June 3, 2024, Ourania Tatsis, EVP, Chief Regulatory & Quality Officer at Vertex Pharmaceuticals Inc. (VRTX), completed a sale of 2,175 shares of common stock at a price of $460 per share. The transaction, conducted on the open market, resulted in a total value of $1,000,500. Following the sale, Tatsis holds a total of 49,098 shares in the company. The sale reflects a direct ownership transaction and is part of the normal course of investment adjustments.
2024年6月3日，Vertex Pharmaceuticals Inc.（简称VRTX）的执行副总裁，首席监管和质量官Ourania Tatsis，以每股460美元的价格卖出2,175股普通股。 这笔交易在公开市场上进行，总价值达1,000,500美元。 销售后，Tatsis总共持有该公司的49,098股。 该销售反映了直接拥有的交易，并是投资调整的正常过程的一部分。
2024年6月3日，Vertex Pharmaceuticals Inc.（简称VRTX）的执行副总裁，首席监管和质量官Ourania Tatsis，以每股460美元的价格卖出2,175股普通股。 这笔交易在公开市场上进行，总价值达1,000,500美元。 销售后，Tatsis总共持有该公司的49,098股。 该销售反映了直接拥有的交易，并是投资调整的正常过程的一部分。
有用
没用

该公告为独立文件：

独立文件1

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息